Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by van Vollenhoven et al

Affiliations

• ¹ Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA jsparks@bwh.harvard.edu zswallace@mgh.harvard.edu.
• ² Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
• ³ Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA jsparks@bwh.harvard.edu zswallace@mgh.harvard.edu.
• ⁴ Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.
• ⁵ Medicine/Rheumatology, University of California San Francisco, San Francisco, California, USA.
• ⁶ Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.
• ⁷ Metro North Hospital & Health Service, Royal Brisbane and Woman's Hospital Health Service District, Herston, Queensland, Australia.
• ⁸ MRC Centre for Neuromuscular Diseases, University College London, London, UK.
• ⁹ Rheumatology, University College London Centre for Rheumatology, London, UK.